VistaGen Therapeutics Inc. (NASDAQ:VTGN)’s traded shares stood at 2.1 million during the last session, with the company’s beta value hitting 1.07. At the close of trading, the stock’s price was $0.15, to imply an increase of 4.74% or $0.0 in intraday trading. The VTGN share’s 52-week high remains $1.79, putting it -1093.33% down since that peak but still an impressive 46.67% since price per share fell to its 52-week low of $0.08. The company has a valuation of $35.76M, with an average of 2.34 million shares in intraday trading volume over the past 10 days and average of 6.80 million shares over the past 3 months.
Analysts have given a consensus recommendation of a Hold for VistaGen Therapeutics Inc. (VTGN), translating to a mean rating of 3.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give VTGN a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 0 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.06.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
VistaGen Therapeutics Inc. (NASDAQ:VTGN) trade information
After registering a 4.74% upside in the last session, VistaGen Therapeutics Inc. (VTGN) has traded red over the past five days. The stock hit a weekly high of 0.1600 this Wednesday, 03/15/23, jumping 4.74% in its intraday price action. The 5-day price performance for the stock is 1.67%, and -33.33% over 30 days. With these gigs, the year-to-date price performance is 48.16%. Short interest in VistaGen Therapeutics Inc. (NASDAQ:VTGN) saw shorts transact 12.4 million shares and set a 1.48 days time to cover.
Analysts on Wall Street suggest a consensus price target of $0.25, implying an increase of 40.0% to the stock’s current value. The extremes give us $0.25 and $0.25 for target low and target high price respectively. As such, VTGN has been trading -66.67% off suggested target high and -66.67% from its likely low.
VistaGen Therapeutics Inc. (VTGN) estimates and forecasts
Looking at statistics comparing VistaGen Therapeutics Inc. share performance against respective industry, we note that the company has underperformed competitors. VistaGen Therapeutics Inc. (VTGN) shares are -19.17% down over the last 6 months, with its year-to-date growth rate lower than industry average at 0.00% against 9.90%. Revenue is forecast to grow 33.30% this quarter before jumping 70.00% for the next one. The rating firms project that company’s revenue will shrink -96.40% compared to the previous financial year.
Revenue forecast for the current quarter as set by 2 analysts is $90k. Meanwhile, for the quarter ending Jun 2023, a total of 1 analyst(s) estimate revenue growth to $180k.Earnings reports from the last fiscal year show that sales brought in $39k and $310k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 130.80% before dropping -41.90% in the following quarter.
VTGN Dividends
VistaGen Therapeutics Inc. has its next earnings report out on February 07. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. VistaGen Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
VistaGen Therapeutics Inc. (NASDAQ:VTGN)’s Major holders
VistaGen Therapeutics Inc. insiders hold 0.84% of total outstanding shares, with institutional holders owning 22.21% of the shares at 22.40% float percentage. In total, 22.21% institutions holds shares in the company, led by Blackrock Inc. As of Sep 29, 2022, the company held over 11.69 million shares (or 5.65% of shares), all amounting to roughly $1.78 million.
The next major institution holding the largest number of shares is Franklin Resources, Inc. with 9.1 million shares, or about 4.40% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $1.38 million.
We also have iShares Russell 2000 ETF and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the VistaGen Therapeutics Inc. (VTGN) shares. Going by data provided on Dec 30, 2022, iShares Russell 2000 ETF holds roughly 4.56 million shares. This is just over 2.20% of the total shares, with a market valuation of $0.47 million. Data from the same date shows that the other fund manager holds a little less at 2.43 million, or 1.17% of the shares, all valued at about 0.37 million.
